






## ORIGINAL RESEARCH

# Genetic dissection of *HLA-DRB1\*15:01* and XL9 region variants in Japanese patients with systemic lupus erythematosus: primary role for *HLA-DRB1\*15:01*

Aya Kawasaki <sup>1,2,3</sup> Premita Ari Kusumawati,<sup>1,2</sup> Yuka Kawamura,<sup>1,3</sup> Yuya Kondo,<sup>4</sup> Makio Kusaoi <sup>5</sup> Hirofumi Amano,<sup>5,6</sup> Yasuyoshi Kusanagi,<sup>7</sup> Kenji Itoh <sup>7</sup>, Takashi Fujimoto,<sup>8</sup> Naoto Tamura <sup>5</sup>, Hiroshi Hashimoto,<sup>9</sup> Isao Matsumoto,<sup>4</sup> Takayuki Sumida,<sup>4</sup> Naoyuki Tsuchiya <sup>1,2,3</sup>

**To cite:** Kawasaki A, Kusumawati PA, Kawamura Y, et al. Genetic dissection of *HLA-DRB1\*15:01* and XL9 region variants in Japanese patients with systemic lupus erythematosus: primary role for *HLA-DRB1\*15:01*. *RMD Open* 2023;9:e003214. doi:10.1136/rmdopen-2023-003214

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/rmdopen-2023-003214>).

Received 8 April 2023  
Accepted 12 May 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

**Correspondence to**

Professor Naoyuki Tsuchiya; [tsuchiya.nyk@gmail.com](mailto:tsuchiya.nyk@gmail.com)

Dr Aya Kawasaki;  
[a-kawasaki@md.tsukuba.ac.jp](mailto:a-kawasaki@md.tsukuba.ac.jp)

**ABSTRACT**

**Objective** Major histocompatibility complex strongly contributes to susceptibility to systemic lupus erythematosus (SLE). In the European populations, *HLA-DRB1\*03:01* and *DRB1\*15:01* are susceptibility alleles, but *C4* locus was reported to account for the association of *DRB1\*03:01*. With respect to *DRB1\*15:01*, strong linkage disequilibrium with a variant rs2105898T in the XL9 region, located between *DRB1* and *DQA1* and regulates HLA-class II expression levels, was reported; however, the causative allele remains to be determined. Leveraging the genetic background of the Japanese population, where *DRB1\*15:01* and *DRB1\*15:02* are commonly present and only *DRB1\*15:01* is associated with SLE, this study aimed to distinguish the genetic contribution of *DRB1\*15:01* and XL9 variants.

**Methods** Among the XL9 variants, two (rs2105898 and rs9271593) previously associated variants in the European populations and two (rs9271375 and rs9271378) which showed a trend towards association in a Japanese Genome-Wide Association Study were selected. Associations of the XL9 variants and *HLA-DRB1* were examined in 442 Japanese SLE patients and 779 controls. Genotyping of the XL9 variants was performed by TaqMan SNP Genotyping Assay and direct sequencing. *HLA-DRB1* alleles were determined by PCR-reverse sequence-specific oligonucleotide probes.

**Results** Among the XL9 variants, associations of rs2105898T and rs9271593C were replicated in the Japanese population. However, these associations became no longer significant when conditioned on *DRB1\*15:01*. In contrast, the association of *DRB1\*15:01* remained significant after conditioning on the XL9 variants.

**Conclusion** In the Japanese population, *HLA-DRB1\*15:01* was found to be primarily associated with SLE, and to account for the apparent association of XL9 region.

**INTRODUCTION**

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease caused by a combination of multiple genetic and

**WHAT IS ALREADY KNOWN ON THIS TOPIC**

- ⇒ The association of *HLA-DRB1\*03:01* with susceptibility to systemic lupus erythematosus (SLE) was reported to be secondarily caused by linkage disequilibrium (LD) with copy number reduction of *C4*, which has the primary role.
- ⇒ It has been hypothesised that the association of *HLA-DRB1\*15:01* with SLE may possibly be caused by LD with XL9 region variants, associated with expression levels of HLA-class II; however, due to strong LD between *DRB1\*15:01* and XL9 variants, this hypothesis could not be addressed in the European populations.

**WHAT THIS STUDY ADDS**

- ⇒ In the Japanese population, two common *DRB1\*15* alleles, *DRB1\*15:01* and *DRB1\*15:02*, are present, both in LD with XL9 variants. However, only *DRB1\*15:01* is associated with SLE.
- ⇒ Leveraging the population difference in the genetic background, we demonstrated that *DRB1\*15:01*, rather than XL9 region variants, is primarily associated with SLE in the Japanese population.

**HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY**

- ⇒ This study provides us with critical information in understanding the respective roles of *HLA* genes and their regulatory regions in the development of SLE.
- ⇒ This study also shows the usefulness of association studies in multiple populations with different genetic backgrounds in the identification of causative variants.

environmental factors. Genetic studies including Genome-Wide Association Studies (GWAS) have identified approximately 180

susceptibility loci for SLE.<sup>1-3</sup> In the European and the African populations, the most significant association was detected in the major histocompatibility complex (MHC) region,<sup>2</sup> where complement *C4* and human leucocyte antigen (*HLA*) loci are located. In the Asian populations, the *GTF2I-NCF1* region was most strongly associated with SLE,<sup>3-5</sup> where *NCF1* p.Arg90His (rs201802880) has been reported to be the causative variant.<sup>5-7</sup> Nevertheless, *MHC* remains one of the top susceptibility regions also in the Asian populations.<sup>3,4</sup>

Among the *HLA* alleles, *HLA-DRB1\*03:01* and *DRB1\*15* have been established as susceptibility alleles to SLE.<sup>8,9</sup> Although *DRB1\*03:01* is associated with SLE in the European populations, *DRB1\*03:01* is rare in the East Asian populations, and significant association of *DRB1\*03:01* is not always detected.<sup>10,11</sup> In contrast, the association of *DRB1\*15:01* is shared between the European and the East Asian populations.<sup>8-11</sup> Further, *DRB1\*15:03* and *DRB1\*15:02* were associated with SLE in the African and the Southeast Asian populations, respectively.<sup>12-14</sup>

Identification of causative allele(s) in the *MHC* region has been challenging, mainly because of the presence of numerous potentially functional variants of *HLA* and non-*HLA* genes, and linkage disequilibrium (LD) that extends from the *MHC class I* to *class II* regions. Thus, each *DRB1* allele is a part of a haplotype that carries multiple potentially functional variants.<sup>8</sup> Most importantly, *C4* genes, *C4A* and *C4B*, reside in the *MHC class III* region and have a copy number variation. A lower copy number of *C4*, especially *C4A*, has been shown to confer risk to SLE.<sup>15,16</sup> In the European populations, due to the strong LD between *C4A* deficient allele and *DRB1\*03:01*, it was impossible to distinguish the genetic contribution of these two loci in the development of SLE. However, leveraging the genetic background of the African-American population, where the LD between *C4A* deficiency and *DRB1\*03:01* is low, Kamitaki *et al* successfully demonstrated that *C4A* deficiency has the primary role, while the association of *DRB1\*03:01* was attributable to the LD with *C4*.<sup>15</sup>

With respect to the other risk haplotype carrying *DRB1\*15:01*, they also detected an association of a single nucleotide variant (SNV), rs2105898T, in the XL9 region between *HLA-DRB1* and *DQA1* loci, both in the European and the African American populations, which was independent of *C4*.<sup>15</sup> The XL9 region risk variants were associated with expression levels of HLA class II molecules. Raj *et al* also demonstrated the association of an SNV in the XL9 region, rs9271593,<sup>17</sup> which is in LD with rs2105898. The XL9 risk variants were in strong LD with *DRB1\*15:01* in the European population; thus, the causative allele among them has not been inferred.<sup>15,17</sup>

In the European and the African populations, *HLA-DRB1\*15:01* and *DRB1\*15:03* account for the majority of *HLA-DRB1\*15*, respectively. In contrast, both *DRB1\*15:01* and *DRB1\*15:02* are commonly present in the Japanese population, of which only *DRB1\*15:01* is associated with susceptibility to SLE.<sup>11</sup> By leveraging genetic background

**Table 1** Characteristics of the patients with SLE and healthy controls

	SLE (n=442)	Healthy controls (n=779)
Male/female	35/399*	304/475
Mean age±SD (years)	42.0±14.0	36.3±11.5
Age of onset (n=377)		
<20 years, n (%)	81 (21.5)	NA
Renal disorder (n=376)		
Present, n (%)	203 (54.0)	NA
Anti-dsDNA antibody (n=363)		
Present, n (%)	298 (82.1)	NA
Anti-Sm antibody (n=362)		
Present, n (%)	75 (20.7)	NA

\*Data were not available for eight patients with SLE. SLE, systemic lupus erythematosus; NA, not applicable.

of the Japanese population, this study was carried out to test whether the association signal of *HLA-DRB1\*15:01* and the XL9 region variant can be distinguished in the Japanese population.

## SUBJECTS AND METHODS

### Patients and controls

A total of 1221 Japanese individuals were analysed, including 442 patients with SLE and 779 healthy controls. Characteristics of the patients and controls are summarised in table 1. Patients' genomic DNA samples were recruited at University of Tsukuba, the University of Tokyo, Juntendo University, Nara Medical University and National Defense Medical College. The patients were diagnosed with SLE according to the 1997 American College of Rheumatology revised criteria for the classification of SLE.<sup>18</sup> In addition, 515 genomic DNA samples were obtained from healthy volunteers at University of Tsukuba, the University of Tokyo and Juntendo University. Aside from that, 264 genomic DNAs were purchased from the National Institute of Biomedical Innovation (Osaka, Japan).

### Genotyping

Genotyping of rs2105898 and rs9271593 was performed by Custom TaqMan SNP Genotyping Assays (Thermo Fisher Scientific, Waltham, Massachusetts, USA) using the QuantStudio 5 Real-Time PCR System (Thermo Fisher Scientific). Genotypes of rs9271375 and rs9271378 were determined by Sanger sequencing. A genomic region surrounding rs9271375 and rs9271378 was amplified and cycle sequencing reaction was conducted using a SupreDye V.3.1 Cycle Sequencing Kit (Edge BioSystems, San Jose, California, USA). Subsequently, sequencing was performed using 3500 Genetic Analyzer (Thermo Fisher Scientific). Primers and probes used in these assays

were listed in online supplemental table S1. *HLA-DRB1* alleles were determined at four-digit resolution by PCR-reverse sequence-specific oligonucleotide probes using a WAKFlow HLA typing kit (Wakunaga Pharmaceutical, Osaka, Japan). The genotyping results of each subject are available in online supplemental data.

### GWAS data on SLE in a Japanese population

GWAS data on 317 Japanese patients with SLE and 175 937 Japanese controls previously reported by Sakaue *et al*<sup>19</sup> were retrieved from the NBDC Human Database (<https://humandbs.biosciencedbc.jp/en/>, Dataset ID: hum0197.v3.gwas.v1, accessed 29 November 2022). Data on variants in a region between *HLA-DRB1* and *HLA-DQA1* encompassing XL9 was extracted.

### Statistical methods

Statistical analyses were carried out by logistic regression analysis with an additive model using the R software V.3.5.2. Association was tested for SLE and its subsets. Correction for multiple testing (four SNVs) was performed by the false discovery rate (FDR) method based on the Benjamini-Hochberg procedure. Significance level was set at  $FDR Q < 0.05$ . The association of haplotypes formed by *HLA-DRB1* and the XL9 variants with SLE was tested by permutation test (the number of permutations was 10 000 000) using Haploview V.4.2 software (Broad Institute, Cambridge, Massachusetts, USA). In LD analysis,  $r^2$  values were calculated by the Haploview software.

Power calculation was done using Quanto V.1.2.4. On the basis of the sample size (442 cases and 779 controls) and previously reported effect size in each study,<sup>15 17 19</sup> this study is assumed to have the power of 73% (rs2105898), 99% (rs9271593), 82% (rs9271375) and 68% (rs9271378)

to detect the association with Bonferroni corrected statistical significance,  $\alpha = 0.0125$ .

## RESULTS

### Association of XL9 variants with SLE

Four XL9 variants were selected for the association analysis between the XL9 region and SLE in the Japanese population. Two of them, rs2105898 and rs9271593, were previously reported to be associated with SLE in the European populations<sup>15 17</sup> and were chosen to examine whether they are also associated in the Japanese population. In addition, in view of differences in the genomic configuration of MHC region between the European and the Asian populations, we employed the GWAS data on Japanese SLE reported by Sakaue *et al*<sup>19</sup> available at the NBDC Human Database (NBDC Dataset ID: hum0197.V.3.gwas.v1 <https://humandbs.biosciencedbc.jp/en/>). In this GWAS, although no XL9 variants reached genome-wide significance, two SNVs, rs9271375 and rs9271378, showed a trend towards association with SLE (online supplemental figure S1 and online supplemental table S2). Thus, the association of rs9271375 and rs9271378 was also tested in this study.

When LD status among the four XL9 variants were tested, LD was observed between rs2105898 and rs9271593 ( $r^2 = 0.676$ ) (online supplemental figure S2.) As shown in table 2, rs2105898T and rs9271593C were significantly associated with risk of SLE after correction for multiple comparisons (FDR  $Q = 0.0067$  and  $0.037$ , respectively). Thus, these SNVs, previously associated in the European populations,<sup>15 17</sup> were found to be associated also in the Japanese. With respect to rs9271375 and rs9271378, the same trend towards the association as observed in the previous Japanese GWAS<sup>19</sup> was also

**Table 2** Association of XL9 variants with SLE

	Genotype				Effect allele	Additive model		
						P value	FDR Q*	OR (95% CI)
rs9271375A/G	A/A	A/G	G/G	A				
SLE (n=442)	39 (8.8)	172 (38.9)	231 (52.3)	250 (28.3)	0.051	0.051	0.84 (0.70 to 1.00)	
Controls (n=779)	78 (10.0)	344 (44.2)	357 (45.8)	500 (32.1)			Referent	
rs9271378G/A	G/G	G/A	A/A	G				
SLE (n=442)	7 (1.6)	84 (19.0)	351 (79.4)	98 (11.1)	0.038	0.051	0.77 (0.59 to 0.98)	
Controls (n=779)	16 (2.1)	187 (24.0)	576 (73.9)	219 (14.1)			Referent	
rs2105898T/G	T/T	T/G	G/G	T				
SLE (n=442)	48 (10.9)	174 (39.4)	220 (49.8)	270 (30.5)	0.0017	0.0067	1.34 (1.12 to 1.61)	
Controls (n=779)	46 (5.9)	291 (37.4)	442 (56.7)	383 (24.6)			Referent	
rs9271593C/T	C/C	C/T	T/T	C				
SLE (n=442)	63 (14.3)	202 (45.7)	177 (40.0)	328 (37.1)	0.018	0.037	1.23 (1.04 to 1.46)	
Controls (n=779)	83 (10.7)	338 (43.4)	358 (46.0)	504 (32.3)			Referent	

\*Significance level was set at FDR  $Q < 0.05$ .  
FDR, false discovery rate; SLE, systemic lupus erythematosus.



**Table 3** Linkage disequilibrium between *DRB1\*15* alleles and XL9 variants and association between *DRB1\*15* alleles and susceptibility to SLE

	LD ( $r^2$ ) with		Association with SLE	
	rs2105898	rs9271593	P value	OR (95% CI)
<i>DRB1*15:01</i>	0.213	0.150	$5.1 \times 10^{-8}$	2.13 (1.62 to 2.80)
<i>DRB1*15:02</i>	0.431	0.288	0.16	0.83 (0.64 to 1.07)

LD, linkage disequilibrium; SLE, systemic lupus erythematosus.

detected in our subjects. However, the difference did not reach statistical significance in our sample set (FDR  $Q=0.051$  for both SNVs) (table 2).

We next tested whether the XL9 variants were associated with the age of onset and presence or absence of renal disorder, anti-dsDNA antibodies and anti-Sm antibodies by a case-case study. As shown in online supplemental table S3, no significant association was detected with the SLE subsets.

### LD between HLA-DRB1 and XL9 variants

*HLA-DRB1\*15* is an established susceptibility allele group to SLE. *DRB1\*15:01* and *DRB1\*15:03* are predominant in the European and the African populations, respectively, while both *DRB1\*15:01* and *DRB1\*15:02* alleles are common in the East Asian populations. The XL9 region is located between the *HLA-DRB1* and *DQA1* loci, and LD is observed between *DRB1\*15* and XL9 variants. We retrieved genotype data on *HLA-DRB1*, rs2105898 and rs9271593 in the Utah residents (CEPH) with Northern and Western European ancestry (CEU), Japanese in Tokyo, Japan (JPT), Han Chinese in Beijing, and Yoruba in Ibadan, Nigeria from the International Genome Sample Resource (2018 data, <https://www.internationalgenome.org/category/hla/>, accessed 28 June 2022) and the Ensembl database (Release 106, <https://asia.ensembl.org/index.html>, accessed 28 August 2022).<sup>20</sup> and calculated  $r^2$  values between each *DRB1\*15* allele and XL9 variant (online supplemental table S4). *DRB1\*15:01* and *DRB1\*15:03* are associated with SLE in the European-ancestry and the African-ancestry populations, respectively,<sup>8 9 12 15</sup> and rs2105898T is associated

with SLE in both populations<sup>15</sup>; however, due to strong LD, association signals from *DRB1\*15* and XL9 variants have not been clearly discriminated in these populations.

In contrast, in the Japanese population, moderate LD was observed between *DRB1\*15* (*\*15:01* and *\*15:02*) and XL9 variants (rs2105898 and rs9271593) (table 3, online supplemental tables S4 and S5 and online supplemental figure S2). Although both *DRB1\*15:01* and *DRB1\*15:02* are commonly present in the Japanese population and in LD with the XL9 variants, *DRB1\*15:01*, but not *DRB1\*15:02*, was associated with SLE (table 3), as previously reported.<sup>11</sup> Therefore, we thought that genetic dissection of *DRB1\*15:01* and XL9 variants might be possible by analysing the Japanese subjects.

### The primary role for HLA-DRB1\*15:01

To address this issue, we conducted a conditional logistic regression analysis to examine whether *DRB1\*15:01* and the XL9 variants are independently associated with SLE. Table 4 shows that the association of *DRB1\*15:01* remained significant after conditioning on rs2105898 ( $P_{\text{conditional}}=7.6 \times 10^{-6}$ ) or rs9271593 ( $P_{\text{conditional}}=8.7 \times 10^{-7}$ ), while that of rs2105898 and rs9271593 became no longer significant when conditioned on *DRB1\*15:01* (rs2105898,  $P_{\text{conditional}}=0.83$ , rs9271593,  $P_{\text{conditional}}=0.93$ ).

Haplotypes formed by *HLA-DRB1\*15:01* and the XL9 variants were also tested for their association with SLE (table 5). *DRB1\*15:01*-rs2105898T-rs9271593C haplotype was significantly increased in SLE compared with healthy controls (permutation  $p=1.0 \times 10^{-7}$ ); however, the haplotype with rs2105898T and rs9271593C risk alleles, but without *DRB1\*15:01*, was not associated with SLE. Taken

**Table 4** Conditional logistic regression analysis of *HLA-DRB1\*15:01* and XL9 variants

	Unconditional		Conditional on <i>DRB1*15:01</i>		Conditional on rs2105898		Conditional on rs9271593	
	P value	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)
<i>HLA-DRB1*15:01</i>	$5.1 \times 10^{-8}$	2.13 (1.62 to 2.80)	NA	NA	$7.6 \times 10^{-6}$	2.09 (1.52 to 2.89)	$8.7 \times 10^{-7}$	2.14 (1.58 to 2.90)
rs2105898T	0.0017	1.34 (1.12 to 1.61)	0.83	1.02 (0.82 to 1.28)	NA	NA	0.035	1.44 (1.03 to 2.05)
rs9271593C	0.018	1.23 (1.04 to 1.46)	0.93	0.99 (0.81 to 1.20)	0.61	0.92 (0.66 to 1.27)	NA	NA

NA, not applicable.

**Table 5** Association between SLE and haplotypes formed by *HLA-DRB1* and XL9 variants, rs2105898 and rs9271593

Haplotype	Frequency (%)		Permutation test*		
	SLE	Controls	P value		
<i>HLA-DRB1</i>	rs2105898	rs9271593			
*15:01	T	C	13.5	6.6	1.0×10 <sup>-7</sup>
Others	T	C	17.0	18.0	0.95
Others	G	C	6.6	7.8	0.65
Others	G	T	62.6	67.5	0.041

\*The number of permutations: 10 000 000.  
SLE, systemic lupus erythematosus.

together, these results suggested that the association of *DRB1\*15:01* has the primary role in the susceptibility to SLE, and the association of the XL9 variants is secondarily caused by LD with *DRB1\*15:01*.

### DISCUSSION

Identification of the causative variant(s) among the *MHC* region remains challenging, due to the presence of multiple potentially functional variants and extensive LD. With respect to *DRB1\*03:01* haplotype in SLE, Kamitaki *et al* reported a primary role for reduced copy number of *C4A* based on the results from the African-American population.<sup>15</sup> However, their study did not determine the causative allele on the *DRB1\*15* haplotype, because of the tight LD with the XL9 region SNV which might regulate expression levels of *HLA-class II* alleles, in the European population. In this study, leveraging the genetic background of the Japanese population, we were able to present evidence for the primary role of the *DRB1\*15:01* allele, rather than the XL9 region SNVs, for the susceptibility to SLE.

The XL9 region shows high histone acetylation levels and interacts with the promoters of *HLA-class II* genes, including *HLA-DRB1* and *DQA1*. Thus, the XL9 region was predicted to impact on transcriptional regulation of nearby *HLA* genes.<sup>21, 22</sup> In fact, the risk alleles for SLE, rs2105898T and rs9271593C, were shown to be associated with expression of *HLA-class II* genes.<sup>15, 17</sup> Whole blood eQTL data from the Genotype-Tissue Expression Portal V.8 (<https://gtexportal.org/home/>, accessed 13 March 2023) are shown in online supplemental table S6. Kamitaki *et al* also reported that a binding site for a transcription factor ZNF143 was disrupted by substituting rs2105898G with T.<sup>15</sup> These data support the functional significance of XL9 variants.

Nevertheless, concerning the susceptibility to SLE, our conditional logistic regression analysis showed that the association of XL9 variants was no longer significant when conditioned on *DRB1\*15:01*, whereas the association of *DRB1\*15:01* remained significant after conditioning on XL9 variants, suggesting that *DRB1\*15:01*, rather than XL9 variants, may be the causative susceptibility allele, at least in the Japanese population.

Consistent with this, although XL9 variants were in LD with both *DRB1\*15:01* and *DRB1\*15:02*, only

*DRB1\*15:01* was significantly associated with SLE susceptibility (table 3). There is only a single amino acid difference at position 86 between *DRB1\*15:01* (86Val) and *DRB1\*15:02* (86Gly). This amino acid sequence difference affects the peptide binding motif (MHC Motif Viewer, <https://services.healthtech.dtu.dk/services/MHCMotifViewer/Home.html>)<sup>23</sup> and T cell receptor repertoire selection.<sup>24</sup> Furthermore, *DRB1\*15:01* was recently reported to be associated with hypomethylation and increased expression of *HLA-DRB1* in monocytes.<sup>25</sup> Taken together, it appears more plausible that *DRB1\*15:01* plays a primary role in the susceptibility to SLE through its effect on antigenic peptide specificity and/or T cell repertoire selection. On the other hand, the possible role for XL9 variants might not be entirely excluded. As shown in table 5, a haplotype carrying *DRB1\*15:01* contains rs2105898T and rs9271593C, and thus it might be possible that by having regulatory XL9 variants together with *DRB1\*15:01* on the same chromosome, the effect of *DRB1\*15:01* could be enhanced as compared with having the non-risk variants of XL9.

Recently, Wang *et al* examined the genetic correlation for SLE between the European and the Chinese populations.<sup>26</sup> The transancestral genetic-effect correlation ( $r_{ge}$ ) was increased from 0.64 to 0.78 when the variants in the *HLA* region were removed from the analysis, suggesting a genetic difference in the *HLA* region between the European and the Chinese populations. The possibility that the role of the XL9 region may also be different among European, African and Asian populations cannot be excluded.

In view of population-specific differences in the genomic configuration of the *MHC* region, the possibility that XL9 variants other than rs2105898T and rs9271593C play a causal role cannot be excluded. Therefore, to comprehensively investigate an association of XL9 variants with SLE, we accessed the previous GWAS data on Japanese SLE<sup>19</sup> and included two SNVs with a tendency towards association, rs9271375 and rs9271378, into our analysis. In our case-control set, although a trend towards association of rs9271378 was observed, the statistical significance did not stand correction for multiple testing. These SNVs were not in LD with *DRB1* alleles associated with SLE in the Japanese population, including *HLA-DRB1\*15* alleles (online supplemental table S5 and online supplemental figure S2); therefore, the possibility that future large-scale studies

might lead to identification of XL9 variant(s) with an independent effect from *DRB1\*15:01* cannot be excluded.

Limitations of this study include a relatively small sample size. Although our sample size is assumed to have 68% or larger power to detect statistical significance based on previously reported effect size for each SNV,<sup>15 17 19</sup> studies in larger sample sizes may be necessary to comprehensively evaluate the independent role of XL9 region. In addition, this study does not provide any explanation on the significant association of *DRB1\*15:02* in Southeast Asian populations.<sup>13 14</sup> Future fine mapping studies on these populations are required.

In summary, we replicated the association of the XL9 variants with SLE in a Japanese population and confirmed the observation reported in the European and the African populations. Taking advantage of the genetic background of the Japanese population, the association of the XL9 variants was suggested to be attributable to LD with *HLA-DRB1\*15:01*, which may play a causative role. These observations further emphasise the transethnic studies' importance in finely mapping causative variants.

#### Author affiliations

<sup>1</sup>Molecular and Genetic Epidemiology Laboratory, Institute of Medicine, University of Tsukuba, Tsukuba, Japan

<sup>2</sup>Master's Program in Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Japan

<sup>3</sup>College of Medical Sciences, University of Tsukuba, Tsukuba, Japan

<sup>4</sup>Department of Rheumatology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan

<sup>5</sup>Department of Internal Medicine and Rheumatology, Faculty of Medicine, Juntendo University, Tokyo, Japan

<sup>6</sup>Department of Internal Medicine and Rheumatology, Juntendo University Nerima Hospital, Tokyo, Japan

<sup>7</sup>Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan

<sup>8</sup>Department of General Medicine, Nara Medical University, Kashihara, Japan

<sup>9</sup>School of Medicine, Juntendo University, Tokyo, Japan

**Contributors** AK, PAK and NTs designed the study, interpreted the data and wrote the manuscript. AK, PAK and YKa performed genotyping and statistical analyses. YKo, MK, HA, YKu, KI, TF, NTA, HH, IM and TS recruited the participants and collected clinical data. All authors read and approved the final version of the manuscript. NTs acts as guarantor of this paper.

**Funding** This study was partly supported by the collaborative research fund from H.U. Group Research Institute G.K., and by award grants given to NTs from Japan College of Rheumatology and Japan Rheumatism Foundation.

**Disclaimer** The funders had no role in the design, analysis, interpretation and paper writing of this study.

**Competing interests** AK has received research grants from Ichiro Kanehara Foundation, Takeda Science Foundation, and Japan College of Rheumatology, and honoraria for lectures from Chugai Pharmaceutical. YKo has received a research grant from GlaxoSmithKline Japan, and honoraria for lectures from GlaxoSmithKline Japan, AstraZeneca and Asahi Kasei Pharma. HA has received consulting fee from Nippon Shinyaku, honoraria for lectures and support for attending meetings and/or travel from Janssen Pharmaceutical, Eli Lilly Japan, Taisho Pharmaceutical, Nippon Boehringer Ingelheim, Eisai, Mitsubishi Tanabe Pharma, Nippon Shinyaku, Chugai Pharmaceutical, Glaxo Smith Kline Pharmaceuticals, Ono Pharmaceutical, Asahi Kasei Pharma, AstraZeneca, AbbVie and Ayumi Pharmaceutical. NTa has received grants from Asahi Kasei Pharma, Asahi Kasei Medical, Ayumi, AbbVie, Eisai, Nippon Boehringer Ingelheim, Taisho, Tanabe Mitsubishi, and Chugai, and honoraria for lectures from Asahi Kasei Pharma, AstraZeneca, AbbVie, Eli Lilly Japan, GlaxoSmithKline, Chugai, Novartis, Bristol-Myers Squibb, and Janssen. KI and YKu have received grants from Asahi Kasei Pharma, Eisai, Teijin Pharma, and Chugai Pharmaceutical. KI has received honoraria for lectures from Asahi Kasei Pharma and AbbVie. NTs has received grants from Bristol-Myers Squibb K.K., the

Naito Foundation, the Uehara Memorial Foundation, and collaborative research fund from H.U. Group Research Institute G.K. NTs has received award grants from Japan College of Rheumatology and Japan Rheumatism Foundation, and honoraria for lectures from Teijin

**Patient consent for publication** Not applicable.

**Ethics approval** This study involves human participants and this study was reviewed and approved by the of University of Tsukuba Institute of Medicine Ethics Committee (approval ID: 122(1), 123, 268). In addition, this study was also approved by the Ethics Committees of the following institutes, which participated in the collaboration and/or recruitment of the subjects: the University of Tokyo, Nara Medical University, Juntendo University and National Defense Medical College. Participants gave informed consent to participate in the study before taking part.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article or uploaded as online supplemental information.

**Author note** A preprint of the manuscript is available at the medRxiv preprint server (medRxiv 2023.04.05.23288103; doi: <https://doi.org/10.1101/2023.04.05.23288103>).

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

#### ORCID iDs

Aya Kawasaki <http://orcid.org/0000-0002-5142-5610>

Makio Kusaoi <http://orcid.org/0000-0003-0064-4765>

Kenji Itoh <http://orcid.org/0000-0002-4122-2983>

Naoto Tamura <http://orcid.org/0000-0003-1729-2954>

Naoyuki Tsuchiya <http://orcid.org/0000-0002-6776-5580>

#### REFERENCES

- Ha E, Bae SC, Kim K. Recent advances in understanding the genetic basis of systemic lupus erythematosus. *Semin Immunopathol* 2022;44:29–46.
- Langefeld CD, Ainsworth HC, Cunninghame Graham DS, *et al*. Transancestral mapping and genetic load in systemic lupus erythematosus. *Nat Commun* 2017;8:16021.
- Yin X, Kim K, Suetsugu H, *et al*. Meta-analysis of 208370 East Asians identifies 113 susceptibility Loci for systemic lupus erythematosus. *Ann Rheum Dis* 2021;80:632–40.
- Sun C, Molineros JE, Looger LL, *et al*. High-density genotyping of immune-related Loci identifies new SLE risk variants in individuals with Asian ancestry. *Nat Genet* 2016;48:323–30.
- Zhao J, Ma J, Deng Y, *et al*. A Missense variant in NCF1 is associated with susceptibility to multiple autoimmune diseases. *Nat Genet* 2017;49:433–7.
- Olsson LM, Johansson ÅC, Gullstrand B, *et al*. A single nucleotide polymorphism in the NCF1 Gene leading to reduced oxidative burst is associated with systemic lupus erythematosus. *Ann Rheum Dis* 2017;76:1607–13.
- Yokoyama N, Kawasaki A, Matsushita T, *et al*. Association of NCF1 polymorphism with systemic lupus erythematosus and systemic sclerosis but not with ANCA-associated vasculitis in a Japanese population. *Sci Rep* 2019;9:16366.
- Fernando MMA, Stevens CR, Sabeti PC, *et al*. Identification of two independent risk factors for lupus within the MHC in United Kingdom families. *PLoS Genet* 2007;3:e192.
- Morris DL, Taylor KE, Fernando MMA, *et al*. Unraveling multiple MHC gene associations with systemic lupus erythematosus: model choice indicates a role for HLA Alleles and non-HLA genes in Europeans. *Am J Hum Genet* 2012;91:778–93.
- Lessard CJ, Sajuthi S, Zhao J, *et al*. Identification of a systemic lupus erythematosus risk locus spanning ATG16L2, FCHSD2, AND P2RY2 in Koreans. *Arthritis Rheumatol* 2016;68:1197–209.

- 11 Furukawa H, Kawasaki A, Oka S, *et al.* Human leukocyte antigens and systemic lupus erythematosus: a protective role for the HLA-DR6 alleles Drb1\*13:02 and \*14:03. *PLoS One* 2014;9:e87792.
- 12 Hanscombe KB, Morris DL, Noble JA, *et al.* Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. *Hum Mol Genet* 2018;27:3813–24.
- 13 Sirikong M, Tsuchiya N, Chandanayingyong D, *et al.* Association of HLA-DRB1\*1502-DQB1\*0501 haplotype with susceptibility to systemic lupus erythematosus in Thais. *Tissue Antigens* 2002;59:113–7.
- 14 Lu LY, Ding WZ, Fici D, *et al.* Molecular analysis of major histocompatibility complex allelic associations with systemic lupus erythematosus in Taiwan. *Arthritis Rheum* 1997;40:1138–45.
- 15 Kamitaki N, Sekar A, Handsaker RE, *et al.* Complement genes contribute sex-biased vulnerability in diverse disorders. *Nature* 2020;582:577–81.
- 16 Vyse TJ, Tsao BP. Complement C4, the major histocompatibility complex, and autoimmunity. *Arthritis Rheumatol* 2022;74:1318–20.
- 17 Raj P, Rai E, Song R, *et al.* Regulatory polymorphisms modulate the expression of HLA class II molecules and promote autoimmunity. *Elife* 2016;5:e12089.
- 18 Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997;40:1725.
- 19 Sakaue S, Kanai M, Tanigawa Y, *et al.* A cross-population atlas of genetic associations for 220 human phenotypes. *Nat Genet* 2021;53:1415–24.
- 20 Cunningham F, Allen JE, Allen J, *et al.* Ensembl 2022. *Nucleic Acids Res* 2022;50:D988–95.
- 21 Majumder P, Gomez JA, Boss JM. The human major histocompatibility complex class II HLA-DRB1 and HLA-DQA1 genes are separated by a CTCF-binding enhancer-blocking element. *J Biol Chem* 2006;281:18435–43.
- 22 Majumder P, Gomez JA, Chadwick BP, *et al.* The insulator factor CTCF controls MHC class II gene expression and is required for the formation of long-distance chromatin interactions. *J Exp Med* 2008;205:785–98.
- 23 Rapin N, Hoof I, Lund O, *et al.* MHC motif viewer. *Immunogenetics* 2008;60:759–65.
- 24 Ishigaki K, Lagattuta KA, Luo Y, *et al.* HLA autoimmune risk alleles restrict the hypervariable region of T cell receptors. *Nat Genet* 2022;54:393–402.
- 25 Kular L, Liu Y, Ruhmann S, *et al.* DNA methylation as a mediator of HLA-DRB1\*15:01 and a protective variant in multiple sclerosis. *Nat Commun* 2018;9:2397.
- 26 Wang Y-F, Zhang Y, Lin Z, *et al.* Identification of 38 novel Loci for systemic lupus erythematosus and genetic heterogeneity between ancestral groups. *Nat Commun* 2021;12:772.